NCT07242469CompletedPhase 1
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
A Multiple Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1403 in Participants With Type 2 Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 15 Sept 2026
Brief summary (registry, in English)
The purpose of this study is to learn about the safety and if people tolerate a study medicine called MK-1403. The study will also measure what happens to MK-1403 in the body of a person with type 2 diabetes (T2D) over time (pharmacokinetic or PK study), and how it affects the amount of high-sensitivity C-reactive protein (hsCRP) in a person's blood.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 53 (actual)
- First submitted
- 17 Nov 2025
- Start date
- 22 Dec 2025
- Primary completion date
- 2 Sept 2026
- Lead sponsor
- Merck Sharp & Dohme LLC
- Diseases
- Type 2 diabetes
- NCT number
- NCT07242469
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 53
- From 22 Dec 2025 to the primary completion date, 2 Sept 2026
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Has Type 1 diabetes mellitus or secondary types of diabetes
- Has a history of congestive heart failure (New York Heart Association \[NYHA\] Class 3 or 4)
- Has history of myocardial infarction, uncontrolled arrhythmias, cardiac revascularization, angina, unstable peripheral arterial disease and/or stroke
- Has history of cancer (malignancy)
- Has positive test(s) for hepatitis B surface antigen (HBsAg), hepatitis C antibodies, or human immunodeficiency virus (HIV)
- Has a history of gastrointestinal (GI) disease which might affect food and drug absorption, or has had gastric bypass or similar surgery
Who the study is looking for
- Has a confirmed diagnosis of Type 2 diabetes mellitus (T2DM)
- Has body mass index (BMI) between 18 and 40 kg/m\^2, inclusive
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Anaheim Clinical Trials ( Site 0006) Coordinator of this site? Confirm its status | Anaheim | United States | Unknown status |
| ProSciento Inc. ( Site 0001) Coordinator of this site? Confirm its status | Chula Vista | United States | Unknown status |
| Advanced Pharma CR, LLC ( Site 0003) Coordinator of this site? Confirm its status | Miami | United States | Unknown status |
| QPS-MRA, LLC ( Site 0004) Coordinator of this site? Confirm its status | South Miami | United States | Unknown status |
| Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0005) Coordinator of this site? Confirm its status | Springfield | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.